Adipocyte Differentiation Protocol
3T3-L1, the standard protocol
| Day | Manipulation | Notes |
|---|---|---|
| −2 | Seed 2–3 × 10⁴ cells/cm² | Uniform density matters more than exact number |
| −1 | Grow to 2 days post-confluence | Contact inhibition is part of the programme |
| 0 | Induction: 0.5 mM IBMX, 1 µM dexamethasone, 10 µg/mL insulin | In 10% FBS, 2–3 days |
| 2–3 | Insulin only, 10 µg/mL | 2 days |
| 5 | Maintenance medium | Refresh every 2–3 days |
| 8–12 | Mature: multilocular droplets | Assess, do not assume |
Confluence is the variable that most often explains failure. Cells induced at 70% confluence differentiate poorly, and the reason is that contact inhibition and the first mitotic clonal expansion are part of the programme, not a technicality.
Human preadipocytes, which are not the same protocol
| Parameter | 3T3-L1 | Human ASC |
|---|---|---|
| Induction length | 2–3 days | 3–7 days |
| IBMX | Required | Often required; some protocols omit |
| Dexamethasone | 1 µM | 1 µM, sometimes omitted |
| Insulin | 10 µg/mL | 1–10 µg/mL, longer |
| Rosiglitazone | Optional | Often included |
| Time to mature | 8–12 days | 14–21 days |
| Differentiation efficiency | Typically 80–95% | Typically 40–80%, donor-dependent |
Caveat on donor variance. Human ASCs from different donors differ several fold in differentiation capacity. If the effect of a treatment is smaller than that spread, the experiment requires multiple donors as biological replicates; otherwise the comparison is between donors.
The cocktail components as experimental variables
| Component | Concentration | Intended action | Confound |
|---|---|---|---|
| IBMX | 0.5 mM | PDE inhibition, raises cAMP | Broad cAMP effects on metabolism and lipolysis |
| Dexamethasone | 1 µM | GR agonist, induces C/EBPδ | Suppresses inflammation; alters lipolysis |
| Insulin | 10 µg/mL | IGF1R/IR signalling | Supraphysiological; desensitises insulin signalling |
| Rosiglitazone | 1 µM | PPARγ agonist | Selects a transcriptional programme; increases lipid capacity |
Dexamethasone is the most consequential. It is present to drive differentiation and it also suppresses inflammatory signalling. A study of "glucocorticoid effects on adipocyte inflammation" that used a dex-containing induction protocol is measuring a second dose on an already-treated cell.
Important distinction. Insulin at 10 µg/mL is roughly 1,700 nM — far above any physiological concentration. Cells differentiated in it have downregulated insulin signalling, which matters when the readout is insulin-stimulated glucose uptake.
QC gates
| Gate | Threshold | Method |
|---|---|---|
| Differentiation efficiency | ≥ 80% (3T3-L1); report for human ASC | BODIPY-positive cells with ≥ 3 droplets, by imaging |
| Droplet morphology | Multilocular, uniform | Imaging; unilocular giant droplets suggest over-differentiation or a different phenotype |
| Adiponectin secretion | Detectable, increasing with days | ELISA, normalised to cell number |
| Insulin-responsive uptake | ≥ 1.5-fold over basal | 2-DG with a full insulin dose–response |
| Lipolytic response | ≥ 2-fold glycerol release with isoproterenol | Glycerol assay |
| Mycoplasma | Negative | Monthly |
A culture that fails the first gate cannot be compared with one that passed: every downstream readout scales with the fraction of differentiated cells.
Readouts, and the normalisation problem
| Readout | Normalise to | Why |
|---|---|---|
| Lipid content (BODIPY area) | Cell number | Lipid per cell, not per well |
| Triglyceride mass | DNA or cell number | Lipid loading changes protein per cell |
| Adiponectin, leptin | Cell number | Protein normalisation is confounded by lipid |
| Glycerol release | Cell number and time | Rate, not amount |
| 2-DG uptake | Cell number; protein is acceptable here | Transport is per cell |
| UCP1 | Protein, plus respiration | Transcript alone is insufficient |
Readout note. Protein normalisation is the default in most labs and it is wrong for secreted adipokines: a lipid-loaded adipocyte has more total protein per cell and less secretion per cell, so a per-microgram value can fall while the per-cell value rises.
Lipolysis: glycerol versus fatty acids
| Measurement | Reports | Limitation |
|---|---|---|
| Glycerol release | Complete hydrolysis of triglyceride | Insensitive to partial hydrolysis and re-esterification |
| Free fatty acid release | Net efflux | Includes partial products; affected by re-esterification and export |
| Both together | The balance | Requires both assays on the same well |
A treatment that raises fatty acid efflux with unchanged glycerol is shifting re-esterification, not increasing hydrolysis. That is a different mechanism, and it is the one that matters for ectopic lipid deposition.
Troubleshooting by symptom
| Symptom | Most likely cause | Diagnostic |
|---|---|---|
| Few droplets at day 8 | Induced before confluence; expired IBMX; high passage | Re-seed and induce 2 days post-confluence; keep passage ≤ 10 |
| Droplets in patches | Uneven seeding density | Map confluence before induction |
| Cells detach during induction | IBMX toxicity at high density; serum lot | Lower IBMX to 0.25 mM; test a new lot |
| Abundant lipid, low adiponectin | Over-differentiation; rosiglitazone effect | Measure both; include a no-rosiglitazone arm |
| No lipolytic response | Dexamethasone carryover; receptor desensitisation | Wash before assay; run an isoproterenol dose–response |
| Spontaneous UCP1 induction | Prolonged rosiglitazone; chronic cAMP | Remove rosiglitazone at day 4; check basal cAMP |
The second row explains most reports of "variable differentiation": density heterogeneity produces patches of differentiated and undifferentiated cells, and the population average moves with the ratio between them rather than with the treatment.
Failures that recur
- • Induction at 70% confluence. Poor and variable differentiation.
- • Differentiation efficiency unreported. All downstream values are scaled by it.
- • Dexamethasone confound ignored in inflammation studies.
- • Insulin at 10 µg/mL used, then insulin sensitivity measured. The cells are desensitised.
- • Protein normalisation for secreted factors.
- • Passage number too high. 3T3-L1 loses differentiation capacity after ~10 passages.
- • Serum lot changed mid-experiment.
Where this connects
- • Adipocyte models article supplies the model-choice logic and the beige evidence standard.
- • Lipid pillar supplies the storage and lipolysis chemistry.
- • Insulin resistance article supplies the dose–response requirement when uptake is the readout.
Scientific interpretation and experimental design
- • Confluence is a variable. Induce at 2 days post-confluence.
- • Report differentiation efficiency. It scales every result.
- • Treat dexamethasone as a treatment. It is not a neutral ingredient.
- • Normalise secretion to cell number.
- • Measure glycerol and fatty acids for lipolysis claims.
- • Use multiple donors for human ASC.
- • Record passage. Capacity declines with it.
Selected references for further reading
- • Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. Cell. 1975;5:19–27.
- • Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Analytical Biochemistry. 2012;425:88–90.
- • Lefterova MI, Lazar MA. New developments in adipogenesis. Trends in Endocrinology and Metabolism. 2009;20:107–114.
- • Schweiger M, et al. Measurement of lipolysis. Methods in Enzymology. 2014;538:171–193.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »